Latest News

• Musella Foundation Brain Tumor Treatment Copayment Assistance program is open!        

  The Musella Foundation Copayment Assistance program is now open to new patients as well as those seeking renewals of their grants. The program helps patients with high grade brain tumors pay for Temodar, Optune, Avastin, and Gleostine (and their generics). For details and to apply, visit braintumorcopays.org.

  
  
• What would I do if diagnosed with a Glioblastoma?        

  These are Al Musella's personal thoughts on what he would do if diagnosed with a Glioblastoma. The document is updated periodically, and this latest update was completed on 10/24/24.

  
  
• UNC Lineberger brings investigative cancer treatment for glioblastoma patients in Southeastern US        

  UNC Lineberger is the third treatment center to complete site activation for the Oral Gallium Maltolate Expanded Access Program! The program is also currently available at Providence Mission Viejo (California) with Dr. Santosh Kesari and at Northwell Health (New York) with Dr. John Boockvar. If you are interested in accessing this program but do not live near one of the 3 open centers, you can ask your doctor to contact eap@imagingbiometrics.com for information on how to join the program. 

  
  
• NuvOx Announces Two New Publications        

  NuvOx Pharma is a company developing a new drug called NanO2. They have a currently recruiting Phase 2b trial called RESTORE, which is testing NanO2 together with standard of care for newly diagnosed glioblastoma. NanO2 was developed based on technology similar to ultrasound contrast agents, but modified to carry and deliver oxygen. The drug is meant to reverse tumor hypoxia, a condition that hinders the effectiveness of radiation and chemotherapy. The study investigators recently published two new journal articles, one to explain how NanO2 works and the other to describe the design and rationale for the Phase 2b clinical trial. 

  
  
• Novocure Announcement        

  In their quarterly financial report, Novocure announced that the FDA granted Breakthrough Device designation for the use of Tumor Treating Fields therapy for brain metastases from non-small cell lung cancer. The Breakthrough Device designation is a special status granted to innovative medical devices that have the potential to more effectively treat life-threatening or irreversibly debilitating conditions and allows for expedited development and review process so these devices can potentially reach patients faster.